Related Experiment Video
Updated: Sep 10, 2025

Fully Endoscopic Mitral Valve Repair with Percutaneous Cannulation of Groin Vessels
Published on: May 26, 2023
Mitomycin C in Ahmed Glaucoma Valve Implant Affects Surgical Outcomes
Wei-Chun Lin1, Sen Yang1, Michelle R Hribar1
1Casey Eye Institute, Department of Ophthalmology, Oregon Health & Science University, 3181 S.W. Sam Jackson Park Rd, Portland, OR 97239, USA.
None:
Glaucoma is the leading cause of irreversible blindness worldwide, and the Ahmed Glaucoma Valve (AGV) implant is one of the most commonly performed surgeries to prevent glaucoma-related visual impairment. Mitomycin C is an anti-fibrotic agent that may prevent failure of AGV. This is a retrospective case-control study to evaluate surgical outcomes for patients undergoing AGV with adjunct mitomycin C (MMC) injections compared to those without MMC. Among the 142 eyes, 50 received adjunct MMC compared to 92 without MMC injections. IOPs at post-operative months 1, 3, and 6 were significantly lower in the MMC eyes (9.40, 12.01, 12.63 mmHg) compared to the No-MMC eyes (16.86, 15.87, 15.65 mmHg; p < 0.01). The number of post-operative glaucoma medications for the MMC group was lower at 1, 3, and 6 months (0.3, 0.4, 0.59) compared to the No-MMC group (0.7, 0.97, 1.05; p < 0.05). The difference in IOP and the number of medications was not statistically significant by 12 months. Adjunct MMC was associated with more transient hypotony but no long-term complications. These findings suggest that adjunct MMC improves short-term but not long-term surgical outcomes in AGV glaucoma implants.
Related Concept Videos
Angle Closure Glaucoma: Treatment
Mitral Stenosis III: Medical Management
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Mitral Regurgitation III: Medical Management
Glaucoma: Overview

